Kennedy DPhil student Chrissy Bolton has been awarded Best Abstract in Basic and Translational Science at the European Alliance of Associations for Rheumatology 2025 (EULAR) conference.
Professor Marco Fritzsche from the Kennedy Institute of Rheumatology, is co-leading a research project that has been awarded a \u00a31.4 million Programme Foundation Award from Cancer Research UK, to investigate how physical forces within tumours affect the ability of a type of white blood cell to attack and eliminate cancer cells.
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs) - a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and revolutionise cancer treatment for patients.
A study has found that a subtype of macrophage is found in the perivascular niche early in the development of inflammatory arthritis, attracting more immune cells and potentially driving inflammation. Targeting these cells with new therapies could be a potential avenue for treating inflammatory arthritis before it develops in severity.
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues\u2014addressing a major challenge in current immunotherapy.
Biophotonic Correlative Optical Platform (BioCOP), which is located at the Rosalind Franklin Institute (the Franklin), has entered its next phase of development of calibration and benchmarking. The instrument is now assembled, and the team will start testing it with model systems and real biological problems.
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
Dr Ashwin Jainarayanan, who last year completed his DPhil studies in Professor Mike Dustin\u2019s research group, has been named in the Forbes 30 Under 30 Europe list in Science and Healthcare (2025). Based on his DPhil work, Ashwin co-founded the company Granza Bio in 2024 alongside Dr. Ashwin Nandakumar and Prof Mike Dustin.
New research from the Kennedy Institute has revealed how two important proteins, TBK1 and IKKe, play a crucial role in preventing premature cell death, which can lead to serious inflammation in the body. The findings are particularly relevant for people with a mutation in the TBK1 gene who often develop multiorgan inflammation caused by excessive cell death even in the absence of any infection.
Researchers at the Kennedy Institute have developed a new computational framework that allows simultaneous analysis of gene expression and mechanical forces within cells and tissues, uncovering insights into how the interplay between transcriptional and mechanical signals guides processes such as cell fate decisions or the formation of spatially distinct tissue compartments.
Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
The\u202fAmerican Association of Immunologists (AAI)\u202fhas recognised the outstanding work of the Kennedy Institute\u2019s Professor of Molecular Immunology Michael Dustin\u202fby naming him a Distinguished Fellow of AAI.
A new study conducted by researchers at the Kennedy Institute of Rheumatology has uncovered a pivotal role of asparagine metabolism in regulating B cell homeostasis and immune response.
Paul joined the Kennedy Institute in September 2024 as part of the Newton-Abraham Visiting Professorship, a prestigious award given by the University of Oxford to the most distinguished scholars in the biological, chemical or medical sciences.
The Kennedy Institute of Rheumatology, together with the nearby Institute of Developmental and Regenerative Medicine (IDRM), hosted an Open Day on 25th October for prospective DPhil students. The event provided an exciting opportunity for potential applicants to get an idea of what it would be like to do a DPhil at Oxford.
In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
A perspectives piece published in the Proceedings of the National Academy of Sciences (PNAS) sheds light on the importance of mechanical forces in the early activation of T cells, a critical part of the immune response.
This August, the annual \u2018From the Laboratory to the Clinic\u2019 conference celebrated 25 years since the first biological therapies were approved for rheumatoid arthritis. The conference brings together a global audience of clinicians and academic and industrial scientists, facilitating discussions to bring novel treatments from bench to bedside.
Dr Kate Coldwell has joined the Oxford Centre for Microbiome Studies at the Kennedy Institute to study the links between liver disease and gut bacteria, having been awarded the Daphne Jackson Fellowship, co-funded by the Kennedy Trust for Rheumatology Research (KTRR) and the Medical Research Council.
Professor Sir Ravinder Maini and Professor Sir Marc Feldmann have jointly received The Royal Society\u2019s Royal Medal (Applied) for inventing anti-TNF therapy to treat rheumatoid arthritis (RA), bringing it from bench to bedside in one of the biggest success stories of modern medicine.
![\"Christine](\"https://www.kennedy.ox.ac.uk/news/dr-chrissy-bolton-wins-best-abstract-award-at-eular-2025-congress/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n